Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxorubicin and Cyclophosphamide (AC) is a combination chemotherapy regimen primarily used in the treatment of various cancers, notably breast cancer. Doxorubicin, an anthracycline, exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, which collectively lead to DNA damage and programmed cell death. Cyclophosphamide, an alkylating agent, forms covalent bonds with DNA, leading to cross-linking of DNA strands and interference with DNA replication and transcription. The synergistic action of these two agents aims to effectively halt cancer cell proliferation and induce cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Doxorubicin and Cyclophosphamide.